S. Nishimura

发表

Crystallographic Approach to Identification of Cyclin-dependent Kinase 4 (CDK4)-specific Inhibitors by Using CDK4 Mimic CDK2 Protein*

T Honma, H. Hirai, K. Fukasawa, 2001, The Journal of Biological Chemistry.

Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.

K. Fukasawa, T. Machida, Y. Iwasawa, 2001, Journal of medicinal chemistry.

Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H.

M. Kitagawa, S. Saitoh, Y. Taya, 1996, European journal of biochemistry.

Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.

K. Fukasawa, S. Nishimura, T. Yoshinari, 1999, Cancer research.

Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.

S. Nishimura, K. Noguchi, H. Suda, 1995, Cancer research.

In vivo Anti‐tumor Activity of a Novel Indolocarbazole Compound, J‐107088, on Murine and Human Tumors Transplanted into Mice

T. Kodera, S. Nishimura, M. Ohkubo, 1999, Japanese journal of cancer research : Gann.

Phosphorylation of E2F-1 by cyclin A-cdk2.

M. Kitagawa, S. Hanks, Y. Taya, 1995, Oncogene.

p53-independent induction of apoptosis by cyclin-dependent kinase inhibition.

Y. Shibata, T. Nakamura, A. Okuyama, 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Identification and cloning of a novel isoform of mouse secretory leukocyte protease inhibitor, mSLPI-beta, overexpressed in murine leukemias and a highly liver metastatic tumor, IMC-HA1 cells.

S. Nishimura, H. Arakawa, M. Morita, 1999, Advances in enzyme regulation.

Distinct Repair Activities of Human 7,8-Dihydro-8-oxoguanine DNA Glycosylase and Formamidopyrimidine DNA Glycosylase for Formamidopyrimidine and 7,8-Dihydro-8-oxoguanine*

H. Aburatani, K. Asagoshi, T. Lindahl, 2000, The Journal of Biological Chemistry.

CMAP: a novel cystatin-like gene involved in liver metastasis.

S. Nishimura, H. Arakawa, M. Morita, 1999, Cancer research.

Cystatin-like metastasis-associated protein mRNA expression in human colorectal cancer is associated with both liver metastasis and patient survival.

T. Utsunomiya, M. Mori, S. Nishimura, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expression of p16INK4a suppresses the unbounded and anchorage-independent growth of a glioblastoma cell line that lacks p16INK4a.

M. Kitagawa, I. Suzuki-Takahashi, H. Higashi, 1997, Biochemical and biophysical research communications.

The consensus motif for phosphorylation by cyclin D1‐Cdk4 is different from that for phosphorylation by cyclin A/E‐Cdk2.

M. Kitagawa, Jun Kato, Y. Taya, 1996, The EMBO journal.

The interactions of E2F with pRB and with p107 are regulated via the phosphorylation of pRB and p107 by a cyclin-dependent kinase.

M. Kitagawa, Y. Taya, A. Okuyama, 1995, Oncogene.

cdc2-like kinase is associated with the retinoblastoma protein.

M. Kitagawa, S. Saitoh, A. Okuyama, 1992, Oncogene.

Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells

S. Nishimura, A. Hirano, H. Arakawa, 2001, Oncogene.

Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents.

C. Bailly, P. Colson, C. Houssier, 1999, Cancer research.

A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.

T Honma, K. Fukasawa, N. Kawanishi, 2001, Journal of medicinal chemistry.

Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.

C. Bailly, P. Colson, J. Chaires, 1999, Journal of medicinal chemistry.

ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport.

S. Nishimura, H. Komatani, Rinako Nakagawa, 2002, Biochemical and biophysical research communications.

Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.

H. Kotani, S. Nishimura, H. Komatani, 2001, Cancer research.

A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.

K. Fukasawa, S. Nishimura, H. Komatani, 1999, Cancer research.

Synthesis and biological activities of NB-506 analogues modified at the glucose group.

T. Honma, S. Nishimura, H. Suda, 2000, Bioorganic & medicinal chemistry letters.

DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin.

A. Okuyama, S. Nishimura, Y. Take, 1996, Biochemical and biophysical research communications.

Sequence‐selective DNA cleavage by a topoisomerase I poison, NB‐506

K. Fukasawa, S. Nishimura, H. Komatani, 1998, International journal of cancer.

Synthesis and biological activities of NB-506 analogues: Effects of the positions of two hydroxyl groups at the indole rings.

T. Honma, S. Nishimura, H. Suda, 1999, Bioorganic & medicinal chemistry letters.

Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506.

S. Nishimura, T. Yoshinari, M. Ohkubo, 1999, Bioorganic & medicinal chemistry letters.

Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole- 5,7(6H)-dione (NB-506): its potent antitumor activities in mice.

S. Nishimura, H. Suda, T. Yoshinari, 1995, Cancer research.

Antimetastatic Effect of a Novel Indolocarbazole (NB‐506) on IMC‐HM Murine Tumor Cells Metastasized to the Liver

S. Nishimura, H. Arakawa, A. Okura, 1996, Japanese journal of cancer research : Gann.

OK-1035, a selective inhibitor of DNA-dependent protein kinase.

A. Okuyama, S. Nishimura, Y. Hamano, 1995, Biochemical and biophysical research communications.

A Constitutive Effector Region on the C-terminal Side of Switch I of the Ras Protein (*)

S. Yokoyama, M. Shirouzu, S. Hattori, 1995, The Journal of Biological Chemistry.

Effects of exogenous p16INK4a on growth of cells with various status of cell-cycle regulators.

M. Kitagawa, I. Suzuki-Takahashi, H. Higashi, 1997, Biochemical and Biophysical Research Communications - BBRC.

The K252a Derivatives, Inhibitors for the PAK/MLK Kinase Family, Selectively Block the Growth of HAS Transformants

R. Jorissen, T. Nheu, A. Burgess, 2002, Cancer journal.

Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins.

S H Kim, S. Kim, Sung-Hou Kim, 1992, Science.

Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506.

S. Nishimura, H. Suda, H. Kawamoto, 1999 .

Cloning and characterization of mammalian 8-hydroxyguanine-specific DNA glycosylase/apurinic, apyrimidinic lyase, a functional mutM homologue.

H. Aburatani, A. Yasui, T. Kodama, 1997, Cancer research.

Human MMH (OGG1) type 1a protein is a major enzyme for repair of 8-hydroxyguanine lesions in human cells.

H. Aburatani, E. Ohtsuka, T. Arai, 1999, Biochemical and biophysical research communications.

Genomic construct and mapping of the gene for CMAP (leukocystatin/cystatin F, CST7) and identification of a proximal novel gene, BSCv (C20orf3).

S. Nishimura, Y. Hara, H. Arakawa, 2000, Genomics.